# Managing Metastases in Advanced Prostate Cancer Expert insights on integrating radiation therapy and multidisciplinary care for metastatic prostate cancer patients. - **Source:** [MedPage Today](https://www.medpagetoday.com) - **Published:** 2026-11-12 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/63f818eb-2f1d-4408-bb9d-0c4861e6d580 ## Systemic Therapy as Backbone Systemic therapy remains the primary approach for metastatic prostate cancer because imaging often fails to detect micrometastases throughout the body. While clinicians previously avoided targeting individual lesions, evolving science now suggests radiation can play a crucial role. Balancing systemic control with localized treatments is essential for managing disease progression effectively. ## Radiation in Metastatic Care Radiation therapy is increasingly integrated into treatment plans, particularly for low-volume de novo metastatic hormone-sensitive prostate cancer. The STAMPEDE trial demonstrated a survival benefit for prostate-directed radiotherapy. Additionally, stereotactic body radiotherapy is utilized for oligoprogressive disease, allowing clinicians to control specific spots without necessarily switching the entire systemic treatment regimen. ## Managing Skeletal Metastases Bones are the most common site for prostate cancer spread, requiring careful management to prevent fractures and pain. Bone-modifying agents like bisphosphonates or RANKL ligands are indicated for patients with osteoporosis or those progressing to castration-resistant disease. Palliative radiation serves as a vital tool for addressing symptomatic bone lesions. ## Communication and Patient Hope Discussing metastatic diagnoses requires honesty regarding the incurable nature of the disease while maintaining focus on long-term outcomes. Although median survival spans years, clinicians must avoid sugarcoating the reality of the condition. Emphasizing that incurable does not mean untreatable helps patients navigate the emotional weight of their diagnosis. ## Identifying Treatment Failure Clinicians must monitor for treatment failure or unmanageable toxicity, which necessitate regimen changes. A red flag occurs when patients experience clinical decline, such as fatigue or weight loss, despite low PSA levels. In such cases, re-imaging is critical to rule out aggressive processes like neuroendocrine differentiation, which requires different therapies. ## Multidisciplinary Team Coordination Managing advanced prostate cancer is a team sport involving radiation oncologists, palliative medicine specialists, and nuclear medicine experts. Palliative care is particularly important for symptom support and improving quality of life. Coordination across these specialties ensures that patients receive comprehensive care that addresses both the cancer and their comfort. ## Emerging Diagnostic Technologies The adoption of PSMA PET scans has significantly enhanced the ability to detect metastatic spread, often identifying lesions earlier than conventional imaging. This diagnostic precision allows for more targeted interventions, such as metastasis-directed therapy. These tools help oncologists decide whether a defined course of radiation can provide a treatment-free interval. ## Future of Shared Decision-Making The evolving landscape of prostate cancer treatment emphasizes shared decision-making between physicians and patients. By aligning treatment goals with quality of life preferences, clinicians can better navigate the complexities of modern therapies. Continuous evaluation of disease burden and patient response remains the standard for providing the best possible clinical outcomes. ## Sources covering this story - https://www.medpagetoday.com/beyond-diagnosis/mcspc/123860 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._